GLP-1 use during early pregnancy may not increase risk of major adverse outcomes Taking GLP-1s during the first trimester of pregnancy does not appear to substantially increase the risk of adverse outcomes, according to a new study led by Harvard T.H
*Correspondence: Baptist Gallwitz [email protected] This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Studies show semaglutide, the active ingredient in Wegovy, can increase certain bacteria, like Akkermansia, in the gut
Across the studies, sterile water, distilled water, blank solvent water, or normal saline were used as control interventions
PMC 10025070